Impact of cutaneous toxicities associated with targeted therapies on quality of life. Results of a longitudinal exploratory study;Impact des toxicités cutanées associées aux thérapies ciblées sur la qualité de vie. Résultats d'une étude pilote longitudinale

Bulletin du Cancer

Volumn 100, Issue 3, 2013, Pages 213-222

  Charles, Cécile ^a,b   Sultan, Serge ^c   Bungener, Catherine ^a   Mateus, Christina ^b   Lanoy, Émilie ^b   Dauchy, Sarah ^b   Verschoore, Michèle ^d   Robert, Caroline ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d L'Oréal Recherche et Innovation   (France)

Author keywords

Cancer; Quality of life; Skin toxicities; Targeted therapies

Indexed keywords

ARTICLE; CANCER CONTROL; CANCER SURVIVAL; EXPLORATORY RESEARCH; HUMAN; LEISURE; LONGITUDINAL STUDY; MOLECULARLY TARGETED THERAPY; PILOT STUDY; QUALITY OF LIFE; SKIN TOXICITY; SOCIAL INTERACTION;

EID: 84876562458     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1709     Document Type: Article

References (34)

1. Institut national du cancer. Situation de la chimiothérapie des cancers en 2010. Collection Rapports et Synthèses (récupé ré du site de l'institut, section Expertises-Publications : http://www.e-cancer.fr).
2. André T. Thérapies ciblées en cancérologie. Une terminologie ambiguë. Rev Med Interne 2009; 30 : 391-2.
3. Deslandres M, Sibaud V, Chevreau C, Delord JP. Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGF. Ann Dermatol Venereol 2008; 1 : 16-24. (Pubitemid 351620943)
4. Mateus C, Robert C. Effets cutanés des nouvelles molécules utilisées en cancérologie. Rev Med Interne 2009; 30 : 401-10.
5. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6 : 491-500. (Pubitemid 40903630)
6. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Cancer 2006; 6 : 803-12. (Pubitemid 44450468)
7. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-Term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009; 161 : 515-21.
8. Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-Targeted therapies in colorectal cancer. Cancer Nurs 2007; 30 : S17-26. (Pubitemid 47196598)
9. Lacouture ME, Basti S, Patel J, Ill AB. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR Inhibitors. J Support Oncol 2006; 4 : 236-8.
10. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, openlabel, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28 : 1351-7.
11. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-food skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13 : 1001-11.
12. Cartwright T, Endean N, Porter A. Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol 2009; 160 : 1034-9.
13. Fortune DG, Richards HL, Griffiths CEM, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perception, coping and alexithymia. Br J Clin Psychol 2002; 41 : 157-74. (Pubitemid 34678696)
14. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with decrement in health-related quality of life. Int J Dermatol 2002; 41 : 151-8. (Pubitemid 34601109)
15. Balagula Y, Lacouture ME, Cotliar JA. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 2010; 8 : 149-61.
16. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60 : 299-305.
17. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137 : 280-4.
18. Sampogna F, Frontani M, Baliva G, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009; 160 : 815-22.
19. Thuné-Boyle ICV, Myers LB, Newman SP. The role of illness beliefs, treatment beliefs, and perceived severity of symptoms in explaining distress in cancer patients during chemotherapy treatment. Behav Med 2006; 32 : 19-29.
20. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Oncology 2007; 21 : 34-6.
21. Huggins RH, Kuzel TM, Anderson RT, West DP, Lacouture ME. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). J Clin Oncol 2008; 26 : 15S.
22. Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 15 : 3916-23.
23. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19 : 1955-61.
24. Romito F, Giulani F, Cormio C, Tullipani C, Mattioli V, Colucci G. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer 2010; 18 : 329-34.
25. Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 98 : 1221-9.
26. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE V4.0), 29 mai 2009 (site Internet). Consultable sur : http://ctep.cancer.gov/protocolDevelopment/electronic-Applications/ctc. htm#ctc-40.
27. Finlay AY, Coles E. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132 : 236-44.
28. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-Type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216 : 366-72. (Pubitemid 351630108)
29. Cayrou S, Dickès P, Dolbeault S. Version française du Profile Of Mood States (POMS-f). J Ther Comportementale Cogn 2003; 13 : 83-8.
30. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX : Psychological Corporation, 1996.
31. American Psychiatric Association (APA). DSM-IV-TR manuel diagnostique et statistique des troubles mentaux : texte révisé. Paris : Masson, 2000.
32. de la Ménardière H, Reich M, Vanlemmens L. Repérage, clinique et évaluation de la dépression en oncologie : collaboration psychiatre, psychologue et cancérologue. Psychooncologie 2010; 4 : 250-5.
33. Basra MKA, Finlay AY. The family impact of skin diseases: the greater patient concept. Br J Dermatol 2007; 156 : 929-37. (Pubitemid 46642834)
34. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008; 21 : 54-9. (Pubitemid 351342175)